Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet NeedGOTHENBURG, Sweden, Sept. 21, 2026 (GLOBE NEWSWIRE) -- As World Alzheimer’s Day highlights the continued unmet need in Alzheimer’s disease, Swedish clinical-stage biopharmaceutical company Alzinova AB (Nasdaq First North: ALZ) is advancing on two fronts: initiating the global Phase II start-up of its therapeutic vaccine ALZ-101 while advancing a blood-based diagnostic program based on the same proprietary technology.
